A Guess At Q1 2024 Earnings, For Merck -- Next Week: Should Be Strong...

This event next week. . . is unlikely to make a big wave in Merck's NYSE stock price, because the dynamics of pembrolizumab's ever rising revenue penetration are pretty well understood, on Wall Street. So -- in the main, the open variables reside in the op. expense / M&A / cap ex. lines (all controllable by the executive team, quarter to quarter). And even as to those smaller ones that are not, Merck's executives have spent about 75 years fine-tuning quarter to quarter levers, to pull should a wrinkle arise.

So, again -- next Thursday morning is barely likely to be news, at all. And you may bet it will not be a train-wreck (though THAT would be. . . news).

Here's at least one analyst's view -- and I'd expect Rahway to meet, and perhaps slightly exceed. . . these figures:

. . .Merck & Co., Inc. will announce its Q1 2024 earnings next Thursday, April 25. Analysts' consensus opinion is that earnings per share will be about $1.99 on a normalized basis, or $1.87 on a GAAP basis, on revenues of ~$15.2 billion. . . .

Big pharma is generally regarded as a strong sector for investment, with most companies driving wide profit margins -- my calculated average net profit margin of the world's 15 biggest pharma companies is 19% -- paying handsome dividends -- my calculated average dividend yield is ~3.1% -- and delivering solid, S&P-beating share price / trading returns. . . .

Onward -- to a wonderful Spring weekend! Be excellent to one another. . . .

नमस्ते